In a paper recently published in Immunity, Ragon researchers found that, in these cases, control is lost after a type of immune cell, known as a cytotoxic T cell, loses the ability to proliferate and kill HIV-infected cells.

Researchers at the Ragon Institute and the Broad Institute showed that the early immune response to SARS-CoV-2, found in the nose, may determine the course of the COVID-19 outcome.

In a paper published today in the journal Nature, a research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists at Walter Reed Army Institute of Research (WRAIR) and the University of São Paulo, demonstrates that two different ZIKV vaccine candidates provided complete protection in mice against a ZIKV strain from Brazil and suggest that a ZIKV vaccine for humans will likely be feasible.

Researchers from the Ragon Institute of MGH, MIT and Harvard and the Perelman School of Medicine at the University of Pennsylvania developed a new Dual CAR T cell immunotherapy that combats HIV infection in humanized mice.